Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Ramamohan V, Mladsi D, Ronquest N, Kamat S, Boklage S. An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia. Hospital Practice. 2017 Aug;45(3):111-7. doi: 10.1080/21548331.2017.1324227
Fernandez-Barres S, Romaguera D, Valvi D, Martinez D, Vioque J, Navarrete-Munoz EM, Amiano P, Gonzalez-Palacios S, Guxens M, Pereda E, Riano I, Tardon A, Iniguez C, Arija V, Sunyer J, Vrijheid M, INMA Project. Mediterranean dietary pattern in pregnant women and offspring risk of overweight and abdominal obesity in early childhood: the INMA birth cohort study. Pediatr Obes. 2016 Dec;11(6):491-9. doi: 10.1111/ijpo.12092
Singh M, Rebordosa C, Bernholz J, Sharma N. Epidemiology and genetics of cystic fibrosis in Asia: in preparation for the next-generation treatments. Respirology. 2015 Nov 6;20(8):1172-81. doi: 10.1111/resp.12656
Candrilli SD, Dhamane AD, Meyers JL, Kaila S. Factors associated with inpatient readmission among managed care enrollees with COPD. Hospital Practice. 2015 Oct;43(4):199-207. doi: 10.1080/21548331.2015.1085797
Bell C, Kurosky SK, Candrilli SD. Muscular dystrophy-related hospitalizations among male pediatric patients in the United States. Hospital Practice. 2015 Aug;43(3):180-5.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Bae JP, Candrilli SD, Fortenberry J, Meyers JL, Jakubowski JA, Drenning D. Point-of-care platelet reactivity determination with VerifyNow-P2Y12® following administration of clopidogrel or prasugrel: data from a real-world, clinical-care inpatient setting. Hospital Practice. 2014 Oct;42(4):7-15. doi: 10.3810/hp.2014.10.1139
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Ganderton L, Jenkins S, McKenna SP, Gain K, Fowler R, Twiss J, Gabbay E. Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Australian and New Zealand population. Respirology. 2011 Nov;16(8):1235-40. doi: 10.1111/j.1440-1843.2011.02030.x